NRC Stoklara Genel Bakış Ticari aşamada bir tıbbi teknoloji şirketi olan Neuronetics, Inc. nöro-sağlık bozukluğu olan hastalar için Amerika Birleşik Devletleri'nde ve uluslararası alanda ürünler tasarlamakta, geliştirmekte ve pazarlamaktadır. Daha fazla detay
Ödüller Risk Analizi + 1 daha fazla risk
Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Neuronetics, Inc. Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Neuronetics Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı US$1.28 52 Haftanın En Yüksek Seviyesi US$4.40 52 Haftanın En Düşük Seviyesi US$0.56 Beta 2.26 1 Aylık Değişim 49.47% 3 Aylık Değişim 87.94% 1 Yıllık Değişim -47.19% 3 Yıllık Değişim -64.58% 5 Yıllık Değişim -67.73% Halka arzdan bu yana değişim -91.51%
Son Haberler & Güncellemeler Neuronetics, Inc. (NasdaqGM:STIM) completed the acquisition of Greenbrook TMS Inc. (OTCPK:GBNH.F) from Madryn Health Partners II (Cayman Feeder), LP, fund managed by Madryn Asset Management, LP, 1315 Capital II, L.P. fund managed by 1315 Capital, LLC, Greybrook Health Inc. and others for $0.58 million. Dec 11
Third quarter 2024 earnings released: US$0.44 loss per share (vs US$0.33 loss in 3Q 2023) Nov 14
Neuronetics, Inc. Provides Standalone Earnings Guidance for the Fourth Quarter and Full Year 2024 Nov 14
Neuronetics, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Oct 30
Neuronetics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1) Oct 06
Neuronetics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1) Oct 05 Daha fazla güncelleme görün Neuronetics, Inc. (NasdaqGM:STIM) completed the acquisition of Greenbrook TMS Inc. (OTCPK:GBNH.F) from Madryn Health Partners II (Cayman Feeder), LP, fund managed by Madryn Asset Management, LP, 1315 Capital II, L.P. fund managed by 1315 Capital, LLC, Greybrook Health Inc. and others for $0.58 million. Dec 11
Third quarter 2024 earnings released: US$0.44 loss per share (vs US$0.33 loss in 3Q 2023) Nov 14
Neuronetics, Inc. Provides Standalone Earnings Guidance for the Fourth Quarter and Full Year 2024 Nov 14
Neuronetics, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Oct 30
Neuronetics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1) Oct 06
Neuronetics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1) Oct 05
Neuronetics, Inc. Expands Health Policies Enhance Tms Therapy Access for Adolescents and Adults Sep 20
Independent Chairman of the Board recently bought €68k worth of stock Sep 16
Insufficient new directors Sep 01
Independent Chairman of the Board recently bought €53k worth of stock Aug 19
Second quarter 2024 earnings released: US$0.33 loss per share (vs US$0.17 loss in 2Q 2023) Aug 13 Neuronetics, Inc. (NasdaqGM:STIM) entered into a definitive arrangement agreement to acquire Greenbrook TMS Inc. (OTCPK:GBNH.F) from Madryn Health Partners II (Cayman Feeder), LP, fund managed by Madryn Asset Management, LP, 1315 Capital II, L.P. fund managed by 1315 Capital, LLC, Greybrook Health Inc. and others for $1 million.
Neuronetics, Inc. to Report Q2, 2024 Results on Aug 12, 2024 Jul 29
Neuronetics, Inc. Announces Aetna Policy Update Expands TMS Availability for Adolescents with Depression Jul 23
Independent Chairman of the Board recently bought €94k worth of stock Jun 10
Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents May 16 Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal Year 2024 May 09
First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.38 loss in 1Q 2023) May 08
Neuronetics, Inc. to Report Q1, 2024 Results on May 07, 2024 Apr 24
Neuronetics, Inc. Announces the Publication of Significant Clinical Findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation Apr 11
Neuronetics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024 Mar 07
Full year 2023 earnings released: US$1.05 loss per share (vs US$1.38 loss in FY 2022) Mar 05
President recently sold €66k worth of stock Feb 27
Neuronetics, Inc. to Report Q4, 2023 Results on Mar 05, 2024 Feb 22
Neuronetics, Inc. to Report Q4, 2023 Results on Mar 05, 2024 Feb 21
Neuronetics Launches Latest Evolution in Its Trakstar® Patient Data Management System Feb 12
President recently sold €55k worth of stock Jan 15
Neuronetics, Inc. Revises Earnings Guidance for the Fourth Quarter and Full Year of 2023 Jan 09
Neuronetics Receives 510(K) Clearance for Neurosite Coil Placement Accessory Dec 19
Neuronetics, Inc. Announces Pharmaceuticals and Medical Devices Agency Approval in Japan Dec 05
Neuronetics, Inc. Announces Pharmaceuticals and Medical Devices Agency Approval in Japan Dec 04
Neuronetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023 Nov 09
Third quarter 2023 earnings released: US$0.33 loss per share (vs US$0.28 loss in 3Q 2022) Nov 09
Neuronetics, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 25
Neuronetics, Inc. Announces the Launch of the NeuroStar Voices Portal Sep 14 Neuronetics, Inc. Provides Revenue Guidance for the Third Quarter of 2023
Second quarter 2023 earnings released: US$0.17 loss per share (vs US$0.39 loss in 2Q 2022) Aug 09 Neuronetics, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 26
Neuronetics, Inc Announces Expanded TMS Therapy Access Through Aetna® Health Plans Jul 22
Neuronetics Receives 510(K) Clearance for Ocd Mt Cap for Neurostar Advanced Therapy Jun 13
First quarter 2023 earnings released: US$0.38 loss per share (vs US$0.41 loss in 1Q 2022) May 11
Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2023 May 10
Executive VP recently sold €55k worth of stock Mar 16
Full year 2022 earnings released: US$1.38 loss per share (vs US$1.22 loss in FY 2021) Mar 08
President recently sold €200k worth of stock Feb 19
Neuronetics Announces Elevation of Sara Grubbs to SVP, Chief Revenue Officer Feb 17
High number of new directors Feb 16
High number of new directors Feb 01
Senior VP recently sold €91k worth of stock Jan 21
Neuronetics, Inc. Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar(R) Advanced Therapy for Mental Health Jan 19
Neuronetics, Inc. Revised Revenue Guidance for the Fourth Quarter and Full Year of 2022 Jan 10
Neuronetics, Inc. Appoints Joseph H. Capper to Its Board of Directors and as Member of the Audit Committee, Effective January 1, 2023 Dec 30
Neuronetics, Inc. Announces New Advancements of NeuroStar Advanced Therapy System Nov 15
Third quarter 2022 earnings released: US$0.28 loss per share (vs US$0.31 loss in 3Q 2021) Nov 09
Neuronetics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022 Nov 09
Neuronetics, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 26
Neuronetics, Inc. Launches Innovations to Neurostar Advanced Therapy’s Proprietary Trakstar Platform Sep 27
Bruce J. Shook Notifies the Board of Directors of Neuronetics, Inc. to Resign from the Board Effective as of October 31, 2022 Aug 27
Second quarter 2022 earnings released: US$0.39 loss per share (vs US$0.29 loss in 2Q 2021) Aug 03
Neuronetics, Inc. Provides Earnings Guidance for the Quarter Ending September 30, 2022 and for the Year Ending December 31, 2022 Aug 03
President recently sold €232k worth of stock Jul 21 Neurostics Inc. Receives U.S. Food and Drug Administration Clearance for Treatment of Anxious Depression
Cannell Capital LLC Communicates with Neuronetics Inc Jun 23
First quarter 2022 earnings released: US$0.41 loss per share (vs US$0.31 loss in 1Q 2021) May 13
Neuronetics, Inc. Provides Earning Guidance for the Second Quarter and Full Year of 2022 May 13
Neurostar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Obsessive-Compulsive Disorder May 12
High number of new directors May 02
Neuronetics, Inc., Annual General Meeting, May 26, 2022 Apr 16 Neuronetics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2022 Mar 10
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 09
Neuronetics, Inc. Announces the Commercial Launch of the MT Cap in the U.S Mar 03
Neuronetics, Inc. to Report Q4, 2021 Results on Mar 08, 2022 Feb 24
Senior VP recently sold €56k worth of stock Jan 28
Neuronetics, Inc. Updates Earnings Guidance for the Fourth Quarter and Full Year of 2021 Jan 12
Neuronetics, Inc. Announces 510(k) Clearance of MT Cap Technology for NeuroStar Advanced Therapy for Mental Health Dec 21
Independent Chairman of the Board recently bought €55k worth of stock Nov 29
Third quarter 2021 earnings released: US$0.31 loss per share (vs US$0.18 loss in 3Q 2020) Nov 10
Neuronetics, Inc Announces New Data Highlights NeuroStar® Advanced Therapy for Mental Health Safety Over H-Coil TMS Sep 23
Independent Chairman of the Board recently bought €85k worth of stock Sep 02
Second quarter 2021 earnings released: US$0.29 loss per share (vs US$0.41 loss in 2Q 2020) Aug 05
Senior VP recently sold €73k worth of stock Aug 01
President recently sold €581k worth of stock Jul 21
Independent Chairman Brian Farley has left the company Jun 05
Independent Director recently sold €77k worth of stock Jun 03
First quarter 2021 earnings released: US$0.31 loss per share (vs US$0.68 loss in 1Q 2020) May 05
Neuronetics Reports revenue guidance for the year 2021 May 05
Neuronetics to Present Clinical Data At the American Psychiatric Association 2021 Annual Meeting Apr 30
Senior VP recently sold €105k worth of stock Mar 17
Neuronetics Enhances TrakSta Cloud Patient Data Management System to Maximize Physician Efficiencies Mar 11 Hissedar Getirileri NRC DE Medical Equipment DE Pazar 7D 15.6% 0.1% 0.5% 1Y -47.2% -7.5% 7.2%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: NRC geçen yıl % -7.5 oranında getiri sağlayan German Medical Equipment sektörünün gerisinde kaldı.
Getiri vs Piyasa: NRC geçen yıl % 7.2 oranında getiri sağlayan German Piyasasının altında performans gösterdi.
Fiyat Oynaklığı Is NRC's price volatile compared to industry and market? NRC volatility NRC Average Weekly Movement 22.6% Medical Equipment Industry Average Movement 6.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
İstikrarlı Hisse Senedi Fiyatı: NRC hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.
Zaman İçindeki Volatilite: NRC 'nin haftalık oynaklığı ( 23% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.
Şirket Hakkında Ticari aşamada bir tıbbi teknoloji şirketi olan Neuronetics, Inc., Amerika Birleşik Devletleri'nde ve uluslararası alanda sinir sağlığı bozukluğu olan hastalar için ürünler tasarlamakta, geliştirmekte ve pazarlamaktadır. Şirket, majör depresif bozukluğu olan yetişkin hastaları tedavi etmek için non-invaziv ve sistemik olmayan ofis tabanlı bir tedavi olan NeuroStar Gelişmiş Terapi Sistemini sunmaktadır. NeuroStar Gelişmiş Terapi Sistemi, beynin ruh haliyle ilişkili belirli bölgelerini uyarmak için tasarlanmış elektrik akımlarını indükleyen darbeli, MRI gücünde bir manyetik alan oluşturmak için transkraniyal manyetik stimülasyon kullanır.
Daha fazla göster Neuronetics, Inc. Temel Bilgiler Özeti Neuronetics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? NRC temel i̇stati̇sti̇kler Piyasa değeri €41.33m Kazançlar(TTM ) -€34.93m Gelir(TTM ) €69.74m
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) NRC gelir tablosu (TTM ) Gelir US$72.71m Gelir Maliyeti US$15.77m Brüt Kâr US$56.94m Diğer Giderler US$93.36m Kazançlar -US$36.42m
Son Raporlanan Kazançlar
Sep 30, 2024
Hisse başına kazanç (EPS) -1.20 Brüt Marj 78.31% Net Kâr Marjı -50.09% Borç/Özkaynak Oranı 490.4%
NRC uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görün
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2024/12/27 17:07 Gün Sonu Hisse Fiyatı 2024/12/27 00:00 Kazançlar 2024/09/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları Neuronetics, Inc. 6 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Michael Gorman BTIG William Plovanic Canaccord Genuity David Turkaly JMP Securities
Göster 3 daha fazla analist 
